1932

Abstract

The advent of modern antibody engineering has led to numerous successes in the application of these proteins for cancer therapy in the 13 years since the first Food and Drug Administration approval, which has stimulated active interest in developing more and better drugs based on these molecules. A wide range of tools for discovering and engineering antibodies has been brought to bear on this challenge in the past two decades. Here, we summarize mechanisms of monoclonal antibody therapeutic activity, challenges to effective antibody-based treatment, existing technologies for antibody engineering, and current concepts for engineering new antibody formats and antibody alternatives as next generation biopharmaceuticals for cancer treatment.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-chembioeng-061010-114142
2011-07-15
2024-06-24
Loading full text...

Full text loading...

/content/journals/10.1146/annurev-chembioeng-061010-114142
Loading
/content/journals/10.1146/annurev-chembioeng-061010-114142
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error